1	Diagnostic accuracy of the Point-of-Care Standard G6PD test TM (SD Biosensor) for
2	Glucose-6-phosphate dehydrogenase deficiency: a systematic review of the literature
3	
5	
4	Short title: Diagnostic accuracy of a Point-of-Care Standard G6PD test
5	
6	Juan Camilo Martínez ^{1*} , Viviana Vélez-Marín ¹ , Mary Lopez-Perez ² , Daniel Felipe Patiño ¹ ,
7	Ivan D. Florez ^{1,3,4,5*}
8	
0	Huit of miles and deliberation for decision making INED Medical December Institute
9	¹ Unit of evidence and deliberation for decision making UNED, Medical Research Institute,
10	School of Medicine, University of Antioquia UdeA
11	² Centre for Medical Parasitology, Department for Immunology and Microbiology, Faculty
12	of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
13	³ Department of Pediatrics, School of Medicine, University of Antioquia UdeA, Av. St 70
14	No. 52-21, Medellin, Colombia.
15	⁴ School of Rehabilitation Science, McMaster University, Hamilton, Canada
16	⁵ Pediatric Intensive Care Unit, Clinica Las Americas-AUNA, Medellin, Colombia
17	*Converge and in a cuthout E mail: iver flame (cutor street - Cathod - Converge
17	*Corresponding author: E-mail: <u>ivan.florez@udea.edu.co</u> . School of medicine,
18	University of Antioquia UdeA, Av. St 70 No. 52-21, Medellin, Colombia.

Abstract

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

Glucose-6-Phosphate Dehydrogenase deficiency (G6PDd) is a common genetic enzymopathy that can induce hemolysis triggered by various factors, including some antimalarial drugs. Although many Point-of-Care (PoC) tests, such as STANDARD G6PDTM manufactured by SD biosensor (StandG6PD-BS), are available to detect G6PDd, its pooled diagnostic test accuracy (DTA) remains unknown. To estimate the DTA of StandG6PD-BS at various thresholds of G6PDd, we conducted a systematic review with a DTA metaanalysis, searching EMBASE, MEDLINE, and SciELO databases up to June 30, 2023. We included studies measuring G6PD activity using StandG6PD-BS (reference test) and spectrophotometry (gold standard) in patients suspected of having G6PDd. We assessed the risk of bias (RoB) of the studies using the QUADAS-2 tool and the certainty of evidence (CoE) with the GRADE approach. Our approach included the estimation of within-study DTA, a random-effect bivariate meta-analysis to determine the pooled sensitivity and specificity for 30%, 70%, and 80% enzyme levels' thresholds, and a graphical analysis of the heterogeneity using crosshair and Confidence Regions on receiver operating characteristic (ROC) space plots. After screening 2,407 reports, we included four studies with 7,864 participants covering all thresholds. Two studies had high RoB in QUADAS-2 domains 2 and 3, and the others had low RoB. We also found low, moderate, and high heterogeneity at the 30%, 70%, and 80% thresholds, respectively. The pooled sensitivity was 99.1% (95%CI 96.9-99.7%, CoE: high), 95.7% (92.0-97.0%, high), and 90% (78.0-96.5%, low) for 30%, 70%, and 80% thresholds, respectively. The pooled specificity was 97.4% (95%CI 95.0; 98.4%, high); 92.9% (85.0-96.4%, high); and 89.0% (76.0-96.0%,

41 moderate) for 30%, 70%, and 80% thresholds, respectively. In conclusion, StandG6PD-BS

is a PoC test with high sensitivity and specificity to detect G6PDd at different thresholds.

Author summary

42

43

44 Glucose-6-Phosphate Dehydrogenase deficiency (G6PDd) is a common genetic disease that 45 can induce the destruction of red blood cells leading to anemia triggered by various factors. 46 including some drugs used for malaria treatment. After a literature search in different 47 databases up to January 31, 2023, we pooled diagnostic test accuracy of the Point-of-Care 48 (PoC) STANDARD G6PDTM test manufactured by SD biosensor (StandG6PD-BS) used 49 to identify the G6PDd. Although two of the four studies included showed a high Risk of 50 Bias related to the index test and the reference standard domains of the QUADAS-2 tool, 51 the pooled sensitivity and specificity for 30%, 70%, and 80% enzyme levels' thresholds 52 were around 90%, with better sensitivity and specificity values for the 30% threshold (99.1% and 97.4%) compared with 70% (95.7% and 92.9%) and 80% (90% and 89%) 53 54 threshold. We found low, moderate, and high heterogeneity at the 30%, 70%, and 80% 55 thresholds. In conclusion, StandG6PD-BS is a PoC test with high sensitivity and specificity 56 to detect G6PDd at different thresholds.

- 57 **Keywords:** systematic review, metanalysis, Glucose-6-phosphate dehydrogenase, malaria,
- 58 Point-of-Care test, STANDARD G6PDTM.

Introduction

59

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79

Glucose-6-phosphate dehydrogenase deficiency (G6PDd) is a genetic disorder linked to the X chromosome, with hemizygous males and homozygous females having a deficient activity phenotype (< 30% of enzyme levels). In contrast, heterozygous females may have a normal (> 80%) or intermediate activity phenotype (30% to 80% enzyme level) (1). Individuals with deficient activity may experience hemolytic episodes triggered by intrinsic or extrinsic factors such as medications or certain foods (2). G6PDd is the most common enzymopathy in humans, with variable frequencies and distinctive region-specific distribution (3). It is particularly common in malaria-endemic regions (1,4), with an estimated frequency of 8%- 10% (~350 to 400 million cases per year) and over 200 identified genetic polymorphisms (5). This overlapping is attributed to the protective effect of G6PDd against malaria (1). Malaria caused by *Plasmodium vivax* is geographically widespread and counts for most cases outside Africa, particularly in the Americas and South-East Asia (6). Primaquine (PQ) and the novel tafenoquine (TQ) are the only two approved drugs for treating hepatic stages and are used for the radical cure of uncomplicated malaria by P. vivax (5,7). However, these drugs may precipitate hemolytic crises in individuals with G6PDd (1,5,7), with the severity of the reaction being proportional to the dose of the medication received and the enzyme genotype (5,7). To ensure safe administration of these drugs, the World Health Organization (WHO) recommends testing for G6PDd in those requiring treatment with PQ (7). This could be achieved by using Point-of-Care (PoC) tests to determine G6PD

81

82

83

84

85

86

87

88

89

90

91

92

93

94

95

96

97

98

99

100

101

activity before administering PO and TO, as has been recommended by multiple studies **(8)**. Several tests are currently available to determine the G6PD activity, but they have different performance (9,10). Since the gold standard for G6PD measurement (spectrophotometry) is not suitable for PoC testing, qualitative tests have been developed with variable diagnostic performance and operational characteristics (11–13). While those tests discriminate between normal and deficient G6PD activity and therefore are sufficient to guide PQ treatment, they may not be dependable enough to prevent drug-induced hemolysis with the introduction of TQ. Consequently, more reliable diagnostic tests are required, and one of such test is the semi-quantitative assay STANDARD G6PDTM (SD biosensor, Republic of Korea), an enzymatic colorimetric assay intended to aid the detection of G6PDd (14). This PoC test provides a numeric measurement of G6PD enzymatic activity and total hemoglobin (Hb) concentration in fresh capillary and venous human whole blood specimens (14) and allows classification of the G6PD activity as deficient, intermediate, or normal according to thresholds provided by the manufacturer (14). Despite the recommendation for PoC quantitative or semi-quantitative testing before administering antimalarial treatment, there is only one synthesis of the diagnostic test accuracy (DTA) of the STANDARD G6PDTM test manufactured by SD Biosensor (StandG6PD-BS) (15) in which the authors pooled the individual results of various studies without a complete systematic review approach, risk of bias, and certainty of evidence assessment. In this systematic review and metanalysis, we estimated the pooled DTA of the StandG6PD-BS for different thresholds of G6PD activity.

103

104

105

106

107

108

109

110

111

112

113

114

115

116

117

118

119

120

121

122

123

Materials and methods Protocol and registration This systematic review and DTA meta-analysis were conducted and reported following the Preferred Reporting Items for Systematic Reviews and Meta-analyses of DTA Studies (PRISMA-DTA) guidelines. The protocol was registered in the PROSPERO database (CRD42022311085). Search and study selection Two authors (JCM, VVM) performed a structured search in MEDLINE (via PubMed), EMBASE, and SciELO databases on August 2nd, 2022, and updated it on January 31, 2023, and on June 30, 2023 without language or date restrictions. Our search strategy is outlined in **Table S1**. We included prospective or retrospective studies that measured G6PD activity levels using the reference standard enzymatic test (spectrophotometry G6PD assay) and the reference test (StandG6PD-BS). The studies must have reported enough data to calculate diagnostic performance measures, i.e., true positives (TP), true negatives (TN), false positives (FP), and false negatives (FN), for at least one threshold (30%, 70%, and 80%) of G6PD activity. Using Rayyan software (Rayyan QCRI, Qatar) (16), two authors screened titles and abstracts retrieved from searches, and only those records considered eligible by both reviewers were retrieved in full texts for the next stage. The same authors (JCM, VVM) reviewed the potentially eligible full texts, independently and in duplicate, based on the pre-specified inclusion criteria. Those studies considered eligible by both reviewers were

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

included. Disagreements were resolved by consensus among the reviewers and with the participation of a third reviewer if needed (MLP, IDF). The same authors (JCM, VVM) independently and in duplicate extracted the data from the included studies using a prespecified data extraction form designed in Google Forms (Google LLC, US), which was discussed and piloted among the research team. For each study, we extracted the following information: first author, year of publication, title. population, data for every threshold recommended by the manufacturer (SD biosensor®), number of participants, age (mean and standard deviation), sex, type of blood sample (venous or capillary), and the data needed for 2x2 contingency tables (TP, FP, FN, and TN). Disagreements in the data extraction process were discussed between the reviewers. Risk of bias assessment and certainty of the evidence Two authors (JCM, VVM) independently assessed the Risk of Bias (RoB) for the included studies using the Quality Assessment of Diagnostic Accuracy Studies 2 (QUADAS-2) tool (17). The QUADAS-2 instrument evaluates the RoB of DTA studies with four domains (patient selection, index test, reference standard, and flow and timing), judging each as high, low, or unclear in risk of bias and concerns regarding applicability. The authors discussed any disagreements and resolved them through consensus. We assessed the Certainty of Evidence (CoE) using the GRADE framework for DTA systematic reviews (18,19). This approach evaluates four criteria: RoB (judged using the QUADAS-2 assessment), indirectness, inconsistency, publication bias and impression, and rates the certainty of the evidence in high, moderate, low, and very low.

Statistical analysis

145

146

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

162

163

164

165

166

We used R Software and the package *mada* (version 4.1.2, The R Foundation for Statistical Computing) for the statistical analyses (20) and the GRADE Pro GDT platform (McMaster University 2015, developed by EvidencePrime, Inc) for creating the Summary of Findings (SoF) tables. First, we calculated sensitivity, specificity, positive likelihood ratio (+LR), negative likelihood ratio (-LR), and diagnostic odds ratio (DOR) at every threshold. The cut-off recommended for the StandG6PD-BS test manufacturer is a valuable tool for therapeutic decisions because enzyme levels define the use of specific treatment. Thus, enzymatic levels above 30% allow using PQ and other drugs at specific doses; levels above 70% allow using TQ and any PQ treatment schedule; and levels above 80% define a normal G6PD activity. Then, we fitted the type of blood sample data at each threshold with the Reistma model (21), a bivariate random-effect meta-analysis. With this approach, we calculated the pooled sensitivity, specificity, +LR, and -LR and their corresponding 95% confidence intervals (95% CI) utilizing model estimations. We used data only from female participants at 70% and 80% thresholds. We pooled the results for venous blood samples because the combined capillary samples were too small and not measured in all the studies. For between-studies heterogeneity, we used visual inspection of forest plots for DTA pooled measures, crosshair plots (sensitivity vs. false positive rate), confidence regions in the Receiver Operating Characteristic (ROC) space, evaluating the overlap in the confidence intervals, and *chi-square* test for homogeneity (p-values < 0.05 were considered significant, and therefore as with heterogeneity). We did not obtain enough studies to fit the sensitivity analysis models as stated in the registered protocol.

Results 167 Search results 168 169 We obtained 2,818 records and after removing duplicates, we screened 2,407 unique 170 reports and identified nine potentially eligible studies. After the full-text assessment, we 171 excluded five and included four studies that met the inclusion criteria for qualitative and 172 quantitative synthesis (Figure 1). 173 Figure 1. PRISMA flow diagram indicating the process of inclusion and exclusion of 174 studies. 175 **Included and excluded studies** 176 We excluded five studies (Table S2) because of the different populations, reference tests, 177 or outcomes (i.e., neither provides DTA measures nor data to calculate them; **Table S2**). 178 **Table 1** summarizes the characteristics of the four included studies (22–25). These studies 179 were conducted in the United States (U.S.) (22,25), United Kingdom (U.K.) (22), Brazil 180 (23), Bangladesh (24), and Thailand (25). In total, they included 3,122 (30% thresholds of 181 the StandG6PD-BS), 2,371 (70%), and 2,371 (80%) participants for each test analysis, 182 respectively. All studies were cross-sectional DTA, two included healthy adults (≥ 18 years 183 old) (22,25), one included participants older than two years (23), and three studies included 184 individuals with known G6PD status (23–25). The reference test used in all the studies was 185 spectrophotometry for the G6PD kit (Pointe Scientific). 186 **Table 1.** Characteristics of included studies

187

189

190

191

192

193

194

195

196

197

198

199

200

201

202

203

204

205

206

207

208

Risk of Bias (RoB) Two studies were judged as high (24,25), and two as low RoB in domain one (22,23) (patient selection) of the OUADAS-2 tool. One study was judged high (24), two unclear (22,25), and one low RoB in domain four (23) (flow and timing). All studies had low RoB and applicability concerns in domains two and three (reference test and standard). This information is presented as a table and diagram using the QUADAS-2 tool resources (Figure 2). **Figure 2.** RoB summary judgements about each included study using QUADAS-2 tool. Diagnostic test accuracy from primary studies and pooled data Sensitivities and specificities from primary studies are presented in **Figure 3**. Sensitivity ranged from 91% to 99%, whereas specificities were from 89% to 97% for 30% and 80% thresholds, respectively. Figure 3 displays the crosshair plot (sensitivity vs. false positive rates) for the three thresholds. Positive and negative LR from studies are presented in Figure S1. Pooled DTA measures for each G6PD activity threshold are described (Table 2). Pooled results showed high DTA measures for all the thresholds being better for lower than the highest threshold. Positive and negative LR ranged from 8.2 to 35.3 and 0.009 to 0.106. The CoE for sensitivity and specificity was high for 30% and 70% thresholds, but for 80% threshold sensitivity was low and specificity was moderate due to concerns in the RoB, indirectness, inconsistency, and imprecision (See **Table S3**).

210

211

212

213

214

215

216

217

218

219

220

221

222

223

We found low, moderate, and high heterogeneity in the results for the 30%, 70%, and 80% thresholds, respectively (Figure 4 and 5). **Table 2.** Pooled DTA values for each threshold defined by StandardTM G6PD (SD Biosensor) test. Figure 3. Pooled Sensitivity and Specificity for StandardTM G6PD (SD Biosensor) in venous blood samples. **Figure 4.** Crosshair plot for each threshold defined by the StandardTM G6PD (SD Biosensor) test. Figure 5. SROC curve (bivariate model) for different Standard G6PD (SD Biosensor) thresholds in venous blood samples.

225

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

241

242

243

244

245

Discussion In this systematic review, we included four studies evaluating 7,864 patients and found that StandG6PD-BS is a semi-quantitative PoC test with high sensitivity and specificity values to detect G6PDd at the different G6PD activity thresholds recommended by the manufacturer (30%, 70%, and 80%). The test showed better performance and CoE for 30% and 70%, compared with the 80% threshold. Likewise, the heterogeneity in the results was low, moderate, and high at 30%, 70%, and 80% thresholds, respectively. The included studies were conducted in both high and low-middle-income countries, and participants were predominantly healthy adults with or without known G6PD status. This allows the decision-makers to assess the potential impact of implementing the StandG6PD-BS PoC test in the general population, particularly for uncomplicated malaria by P. vivax. The evidence suggests that introducing this test in tropical and subtropical malaria-endemic countries with P. vivax high transmission regions would be both feasible and desirable and could provide numerous benefits (5,7,26). For instance, a recent study in Brazil (26) found that combining TQ treatment with the StandG6PD-BS test improved the response to radical cure treatment by enhancing adherence, reducing relapses, and increasing protection against new P. vivax infections. The literature describes factors related to lower test accuracy that may not be explained just by the PoC test performance. A recent controlled study suggested that the StandG6PD-BS test performed well in venous blood, exhibiting good repeatability and inter-laboratory reproducibility (27). However, the same study found that the reliability of the test was poor in discriminating between intermediate and low G6PD activities in lyophilized samples

247

248

249

250

251

252

253

254

255

256

257

258

259

260

261

262

263

264

265

266

267

(27), emphasizing the need for further research in field-based scenarios. This study found similar estimates for sensitivity and specificity as reported by Addisu et al. (15). However, our work is the first to conduct a complete systematic review approach through a comprehensive search and selection, a random model meta-analysis, risk of bias assessment, and certainty of evidence using the GRADE approach and following the methods recommended by the Cochrane collaboration. In our approach, we pooled only results of venous blood samples because other sources, such as capillary and lyophilized blood, provided limited results due to small sample sizes in the studies and differences in the specimen collection and lyophilization methods. Nevertheless, some evidence suggests that capillary and lyophilized blood samples could drive less accuracy in the PoC test results (22,27–29). In the included studies, only one (25) used frozen venous blood to run the StandG6PD-BS test showing slightly less DTA than the fresh venous blood samples (25). This could be due to the small number of participants, the specimen collection, or the storage method. An alternative cause is the study population (Thailand), which carries the G6PDd Mahidol phenotype with moderate enzymatic activity (30-70%). However, the StandG6PD-BS sensibilities and specificities at those levels are still around 90% (22,27,30). The current evidence strongly supports the implementation of the PoC test for G6PD activity. At the individual level, it will enable the safe treatment of more patients with deficient and intermediate G6PD activity, diminishing the risk of recurrent malaria and acute hemolytic anemia (5.7,31,32). At the healthcare systems level, it could reduce the associated costs and the burden on transfusion services by reducing the number of

269

270

271

272

273

274

275

276

277

278

279

280

281

282

283

284

285

286

287

288

289

290

hemolytic crises caused by PO or TO in individuals with unknown G6PD status and malaria treatment (5,7,31,33). Additionally, this could impact parasite transmission rates when combined with other interventions (5,7,31). Given that up to 50% of the patients with P. vivax malaria may experience relapses (5.7), administering radical cure with PO or TO is essential for stopping morbidity-related and community transmission (5,7,26,32). Our work has several strengths. This systematic review with meta-analysis is the first to evaluate the DTA of the StandG6PD-BS test. Moreover, we followed state-of-the-art methodologies for conducting DTA studies, as recommended by the Cochrane Handbook for Systematic Reviews of Diagnostic Test Accuracy (34). We prepared the final report of this review following the recommendations by the PRISMA-DTA statement (35). We also provided information on the pooled sensitivity and specificity for each threshold, which can facilitate decision-making in different clinical scenarios. We also recognize some limitations. First, the number of studies was low, preventing us from performing additional analyses, such as sensibility analysis. Additionally, the quality of some studies was not optimal, although our analysis is robust enough to show adequate pooled DTA measures for venous blood samples. Future studies using capillary and lyophilized blood, along with field-based studies, are needed to determine the appropriate usage of this test. A study on barriers and facilitators for G6PD test implementation (36) identified three main barriers: perceived low risk of hemolysis, wrong perception of P. vivax malaria as a benign condition, and the cost of routine testing as part of the healthcare attention of malaria patients. A study conducted in Brazil on the operational challenges associated with pragmatic G6PD testing (37) found that the StandG6PD-BS PoC test was well accepted by both healthcare professionals and patients and can be performed at

malaria treatment units in the Brazilian Amazon to inform treatment decisions with PQ. However, the authors found limitations linked to technical and cultural aspects that should be addressed when expanding screening to larger areas (37).

Conclusion

StandG6PD-BS is a PoC test with high sensitivity and specificity to detect G6PDd at the different thresholds recommended by the manufacturer (30%, 70%, and 80%).

Implementing this kind of test in malaria-endemic areas can lead to early diagnosis of G6PDd, help to prevent hemolytic episodes triggered by PQ or TQ, and potentially impact malaria transmission.

301

302

303

304

305

306

307

308

309

310

311

312

313

314

315

316

317

318

319

Acknowledgments We acknowledge Dr Lina Gaviria (Haematologist, Universidad de Antioquia, Colombia), for their contribution to the conceptualization of this study; Marina Figueira, and Camilo Manchola (Global Health Strategies), Jonathan Novoa (Medicines for Malaria Venture), and Jamil Barton and Reina Jara (Program for Appropriate Technology in Health) for their contribution in this study. **Data Availability Statement** The data are available on request from the authors. Funding This work and its authors (JCM, VVM, MLP, DPL, IDF) were supported, in whole part, by the Bill & Melinda Gates Foundation through a sub-agreement with Global Health Strategies (GHS) as part of the project: "Cost-effectiveness of Tafenoquine in the radical cure of *Plasmodium vivax* malaria" (Grant Number OPP1194815). Under the grant conditions of the Foundation, a Creative Commons Attribution 4.0 Generic License has already been assigned to the Author Accepted Manuscript version that might arise from this submission (https://globalhealthstrategies.com). MLP is supported by Independent Research Fund Denmark (grant 013400123B; https://dff.dk/en). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

320 **Competing interest** 321 The authors declare no competing interests. 322 **Author's contributions** 323 Conceptualization: JCM, IDF. 324 Data curation: JCM, VVM. 325 Formal analysis: JCM, VVM, IDF, MLP 326 Funding acquisition: IDF, DFP. 327 **Investigation:** IDF, DFP, JCM, VVM. 328 Methodology: JCM, VVM. 329 **Project administration:** JCM. 330 Resources: IDF. 331 **Software:** JCM 332 Supervision: IDF, DFP. Visualization: JCM, VVM. 333 334 Writing – original draft: VVM, JCM. 335 Writing – review & editing: JCM, VVM, DFP, IDF, MLP. 336 ORCID IDs:

337 JCM: ttps://orcid.org/0000-0001-6420-7797

338 VVM: https://orcid.org/0000-0002-9430-3912

339 MLP https://orcid.org/0000-0002-9876-0248

340 DFP: https://orcid.org/0000-0003-4030-4255

341 IDF: https://orcid.org/0000-0002-0751-8932

344

345

346

347

348

349

350

351

352

353

354

355

356

357

358

359

360

361

362

363

364

References 1. Howes RE, Battle KE, Satyagraha AW, Baird JK, Hay SI. Chapter Four - G6PD Deficiency: Global Distribution, Genetic Variants and Primaquine Therapy. In: Hay SI, Price R, Baird JKBT-A in P, editors. The Epidemiology of Plasmodium vivax [Internet]. Academic Press; 2013. p. 133–201. Available from: https://www.sciencedirect.com/science/article/pii/B9780124078260000047 2. Bancone G. Chu CS. G6PD Variants and Haemolytic Sensitivity to Primaguine and Other Drugs. Front Pharmacol. 2021;12:638885. 3. Nkhoma ET, Poole C, Vannappagari V, Hall SA, Beutler E. The global prevalence of glucose-6-phosphate dehydrogenase deficiency: A systematic review and metaanalysis. Blood Cells, Mol Dis [Internet]. 2009;42(3):267–78. Available from: https://www.sciencedirect.com/science/article/pii/S1079979609000059 4. Howes RE, Dewi M, Piel FB, Monteiro WM, Battle KE, Messina JP, et al. Spatial distribution of G6PD deficiency variants across malaria-endemic regions. Malar J [Internet]. 2013;12(1):418. Available from: https://doi.org/10.1186/1475-2875-12-418 5. Chu CS, White NJ. The prevention and treatment of Plasmodium vivax malaria. PLoS Med. 2021;18(4 April):1–21. 6. World Health Organization (WHO). World Malaria Report 2023. 2023. Organización Mundial de la Salud OMS. Testing for G6PD deficiency for safe use of 7. primaquine in radical cure of P. vivax and P. ovale malaria Policy brief. Geneva; 2016.

365 8. Malaria Policy Advisory Committee Meeting. Point-of-care G6PD testing to support 366 safe use of primaguine for the treatment of vivax malaria. Geneve: 2015. 367 9. LaRue N, Kahn M, Murray M, Leader BT, Bansil P, McGray S, et al. Comparison of 368 Ouantitative and Oualitative Tests for Glucose-6-Phosphate Dehydrogenase 369 Deficiency. Am Soc Trop Med Hyg [Internet]. 2014;91(4):854–61. Available from: 370 https://www.ajtmh.org/view/journals/tpmd/91/4/article-p854.xml 371 10. Espino FE, Bibit J-A, Sornillo JB, Tan A, von Seidlein L, Ley B. Comparison of 372 Three Screening Test Kits for G6PD Enzyme Deficiency: Implications for Its Use in 373 the Radical Cure of Vivax Malaria in Remote and Resource-Poor Areas in the 374 Philippines. PLoS One [Internet]. 2016;11(2):1–12. Available from: 375 https://doi.org/10.1371/journal.pone.0148172 376 11. Osorio L, Carter N, Arthur P, Bancone G, Gopalan S, Gupta SK, et al. Performance 377 of BinaxNOW G6PD Deficiency Point-of-Care Diagnostic in P. vivax-Infected 378 Subjects. Am Soc Trop Med Hyg [Internet]. 2015;92(1):22–7. Available from: 379 https://www.ajtmh.org/view/journals/tpmd/92/1/article-p22.xml 380 12. Ley B, Bancone G, von Seidlein L, Thriemer K, Richards JS, Domingo GJ, et al. 381 Methods for the field evaluation of quantitative G6PD diagnostics: a review. Malar J 382 [Internet]. 2017;16(1):361. Available from: https://doi.org/10.1186/s12936-017-383 2017-3 384 13. Brito MAM, Peixoto HM, de Almeida ACG, de Oliveira MRF, Romero GAS, 385 Moura-Neto JP, et al. Validation of the rapid test Carestart(tm) G6PD among malaria 386 vivax-infected subjects in the Brazilian Amazon. Rev Soc Bras Med Trop [Internet]. 387 2016 Jul 1 [cited 2022 Oct 21]:49(4):446–55. Available from:

388 http://www.scielo.br/j/rsbmt/a/5pRMgmmgJbk7LvHNBwPXCVD/?lang=en 389 14. PATH. G6PD Operational Research Community of Practice. 2022. 390 15. Adissu W, Brito M, Garbin E, Macedo M, Monteiro W, Mukherjee SK, et al. 391 Clinical performance validation of the STANDARD G6PD test: A multi-country 392 pooled analysis. PLoS Negl Trop Dis [Internet]. 2023 Oct 12;17(10):e0011652. 393 Available from: https://doi.org/10.1371/journal.pntd.0011652 394 16. Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan---a web and 395 mobile app for systematic reviews. Syst Rev [Internet]. 2016;5(1):210. Available 396 from: http://dx.doi.org/10.1186/s13643-016-0384-4 397 Whiting P, Rutjes A, Westwood M, Mallett S, Deeks J, Reitsma J, et al. OUADAS-17. 398 2: A Revised Tool for the Quality Assessment of Diagnostic Accuracy Studies. Ann 399 Intern Med [Internet]. 2011;155(8):529–36. Available from: 400 https://www.acpjournals.org/doi/abs/10.7326/0003-4819-155-8-201110180-00009 401 18. Schünemann HJ, Mustafa RA, Brozek J, Steingart KR, Leeflang M, Murad MH, et 402 al. GRADE guidelines: 21 part 1. Study design, risk of bias, and indirectness in 403 rating the certainty across a body of evidence for test accuracy. J Clin Epidemiol 404 [Internet]. 2020 Jun 1;122:129–41. Available from: 405 https://doi.org/10.1016/j.jclinepi.2019.12.020 406 19. Schünemann HJ, Mustafa RA, Brozek J, Steingart KR, Leeflang M, Murad MH, et 407 al. GRADE guidelines: 21 part 2. Test accuracy: inconsistency, imprecision, 408 publication bias, and other domains for rating the certainty of evidence and 409 presenting it in evidence profiles and summary of findings tables. J Clin Epidemiol

410 [Internet]. 2020 Jun 1;122:142–52. Available from: 411 https://doi.org/10.1016/j.jclinepi.2019.12.021 412 20. Doebler P. mada: Meta-Analysis of Diagnostic Accuracy [Internet]. 2020. Available 413 from: https://cran.r-project.org/package=mada 414 Reitsma JB, Glas AS, Rutjes AWS, Scholten RJPM, Bossuyt PM, Zwinderman AH. 21. 415 Bivariate analysis of sensitivity and specificity produces informative summary 416 measures in diagnostic reviews. J Clin Epidemiol [Internet]. 2005 Oct 1;58(10):982-417 90. Available from: https://doi.org/10.1016/j.jclinepi.2005.02.022 418 Pal S, Myburgh J, Bansil P, Hann A, Robertson L, Gerth-Guyette E, et al. Reference 22. 419 and point-of-care testing for G6PD deficiency: Blood disorder interference, 420 contrived specimens, and fingerstick equivalence and precision. PLoS One. 421 2021;16(9 September):1-24. 422 23. Zobrist S, Brito M, Garbin E, Monteiro WM, Clementino Freitas S, Macedo M, et al. 423 Evaluation of a point-of-care diagnostic to identify glucose-6-phosphate 424 dehydrogenase deficiency in Brazil. PLoS Negl Trop Dis [Internet]. 2021;15(8):1– 425 21. Available from: https://doi.org/10.1371/journal.pntd.0009649 426 24. Alam MS, Kibria MG, Jahan N, Thriemer K, Hossain MS, Douglas NM, et al. Field 427 evaluation of quantitative point of care diagnostics to measure glucose-6-phosphate 428 dehydrogenase activity. PLoS One [Internet]. 2018;13(11):1–13. Available from: 429 https://doi.org/10.1371/journal.pone.0206331 430 25. Pal S, Bansil P, Bancone G, Hrutkay S, Kahn M, Gornsawun G, et al. Evaluation of 431 a Novel Quantitative Test for Glucose-6-Phosphate Dehydrogenase Deficiency:

- Bringing Quantitative Testing for Glucose-6-Phosphate Dehydrogenase Deficiency
- Closer to the Patient. Am J Trop Med Hyg [Internet]. 2018;100(1):213–21.
- 434 Available from: https://www.ajtmh.org/view/journals/tpmd/100/1/article-p213.xml
- 435 26. Nekkab N, Lana R, Lacerda M, Obadia T, Sigueira A, Monteiro W, et al. Estimated
- 436 impact of tafenoquine for Plasmodium vivax control and elimination in Brazil: A
- 437 modelling study. PLoS Med. 2021;18(4):1–19.
- 438 27. Ley B, Satyagraha AW, Kibria MG, Armstrong J, Bancone G, Bei AK, et al.
- Repeatability and reproducibility of a handheld quantitative G6PD diagnostic. PLoS
- 440 Negl Trop Dis. 2022;16(2):1–17.
- 28. Drain PK, Hyle EP, Noubary F, Freedberg KA, Wilson D, Bishai WR, et al.
- Evaluating Diagnostic Point-of-Care Tests in Resource-Limited Settings. Lancet
- 443 Infect Dis. 2014 Mar; 14(3):239–49.
- 444 29. Jameel F, Alexeenko A, Bhambhani A, Sacha G, Zhu T, Tchessalov S, et al.
- Recommended Best Practices for Lyophilization Validation 2021 Part II: Process
- 446 Qualification and Continued Process Verification. AAPS PharmSciTech.
- 447 2021;22(8).
- 448 30. Aung TH, Suansomjit C, Tun ZM, Hlaing TM, Kaewkungwal J, Cui L, et al.
- Prevalence of G6PD deficiency and diagnostic accuracy of a G6PD point-of-care test
- among a population at risk of malaria in Myanmar. Malar J. 2023;22(1):143.
- 451 31. Garcia LS. Malaria. Clin Lab Med. 2010;30(1):93–129.
- 452 32. Llanos-Cuentas A, Manrrique P, Rosas-Aguirre A, Herrera S, Hsiang MS.
- Tafenoquine for the treatment of Plasmodium vivax malaria. Expert Opin

454 Pharmacother. 2022;23(7):759-68. 455 Peixoto HM. Brito MAM. Romero GAS. Monteiro WM. de Lacerda MVG. de 33. 456 Oliveira MRF. Rapid diagnostic test for G6PD deficiency in Plasmodium vivax-457 infected men: a budget impact analysis based in Brazilian Amazon. Trop Med & Int 458 Heal [Internet]. 2017;22(1):21–31. Available from: 459 https://onlinelibrary.wiley.com/doi/abs/10.1111/tmi.12800 460 34. Cochrane Handbook for Systematic Reviews of Diagnostic Test Accuracy 461 Cochrane Training [Internet]. [cited 2022 Aug 14]. Available from: 462 https://training.cochrane.org/handbook-diagnostic-test-accuracy 463 35. McInnes MDF, Moher D, Thombs BD, McGrath TA, Bossuyt PM, Group and the 464 P-D. Preferred Reporting Items for a Systematic Review and Meta-analysis of 465 Diagnostic Test Accuracy Studies: The PRISMA-DTA Statement. JAMA [Internet]. 466 2018 Jan 23;319(4):388–96. Available from: 467 https://doi.org/10.1001/jama.2017.19163 468 36. Ley B, Thriemer K, Jaswal J, Poirot E, Alam MS, Phru CS, et al. Barriers to routine 469 G6PD testing prior to treatment with primaguine. Malar J. 2017;16(1):1–10. 470 37. Brito-Sousa JD, Murta F, Vitor-Silva S, Sampaio V, Mendes M, Souza B, et al. 471 Quantitative G6PD Deficiency Screening in Routine Malaria Diagnostic Units in the 472 Brazilian Amazon (SAFEPRIM): An Operational Mixed-Methods Study. Pathogens. 473 2022;11(11). 474

Figure 1. PRISMA flow diagram indicating the process of inclusion and exclusion of studies.




Figure 2. Risk of Bias summary judgements about each included study using

QUADAS-2 tool. QUADAS-2: Quality Assessment of Diagnostic Accuracy Studies version

2






Figure 3. Pooled Sensitivity and Specificity for Standard[™] G6PD (SD Biosensor) in venous blood samples. Forest Plot for displaying the sensitivity and specificity per study according to specific thresholds with their corresponding 95% CI

30% Threshold





80% Threshold



Figure 4. Crosshair plot for each threshold defined by the StandardTM G6PD (SD Biosensor) test. DTA combined compared thresholds for StandardTM G6PD (SD Biosensor) in venous blood samples The crosshair plot colors correspond to thresholds: blue to 30%, green to 70%, and red to 80%.




Figure 5. SROC curve (bivariate model) for different thresholds for StandardTM

G6PD (SD Biosensor) in venous blood samples. Summary receiver operating characteristic (SROC) curve summarizing sensitivity and false positive rates according to the three thresholds, with the corresponding 95% confidence contour.




Table 1. Characteristics of included studies

First Author	Year	Study type	Countries	Study context	Inclusion criteria	Sample type	Threshold	N for test operative characteristics (2x2 tables)					Reference (index) test	Gold Standard	Observation	Funding
								TP	FN	FP	TN	Total				
Pal (21)	2021	Cross- sectional DTA	U.S. (three clinical centers) U.K.	Healthy volunteers blood denors in different clinical centers	Healthy adults, ≥ 18 years old. They signed written informed consent.	Venous	30%	56	0	26	708	790	STANDARD™ Spectrophotometry for G6PD G6PD using the kit (SD Biosensor) Pointe Scientific	G6PD using the kit		UK's FCDO, Bill & Melinda Gates fdn.
							70%	82	1	49	658	790				
							80%	85	16	58	631	790				
Zobrist (22)	2021	Cross- sectional DTA	Brazil	Febrile patients seeking care at the Manuus (924) and Porto Velho clinics (812)	Participants ≥ 2 years old plus 69 belonged through an enriched sample for G6PD		30%	56	0	23	1583	1662	G6PD G6F	G6PD using the kit Pointe Scientific	temperature and	UK's FCDO, Bill & Melinda Gates fdn., the National Institutes of Health
							70%	31	1	31	848	911				
					known status.		80%	41	20	21	829	911				
Alam (23)	2018	Cross- sectional DTA	Bangladesh	Participants were recruited in the Chittagong Hill Tracts districts (south- eastern)	Convenience sample from a cohort of adult with known G6PD status.	Venous	30%	30	0	0	76	106	G6PD usin	Spectrophotometry for G6PD using the kit Pointe Scientific		s in Australian DFAT, Bill & Melinda Gates fdn.
							70%	48	3	8	47	106		Tome Seemine	stored at room temperature (24	
							80%	58	3	9	36	106			to 26°C) and 4°C.	
Pal (24)	2018	Cross- sectional DTA	U.S.	Healthy volunteers blood donors in two clinical centers (New York and Miami)	Healthy adults, ≥ 18 years old, with an African American origin.		30%	84	0	10	320	414	GGPD GGPD u (SD Biosensor) Pointe S Thailan	Spectrophotometry for G6PD using the kit Pointe Scientific (for Thailand, the Trinity Biotech assay was used).		UK's DFID, Bill & Melinda Gates fdn., MORU-Welkome Trust
							70%	105	5	9	295	414				
							80%	115	6	40	253	414				
		Cross- sectional DTA	Thailand	two clinical centers located north and south of Mae Sot that serve a	study to achieve a	venous blood 70%	30%	54	0	5	91	150				
							70%	96	5	9	40	150				
							80%	103	4	11	32	150				

Abbreviations: TP: True Positives; FN: False Negatives; FP: False Positives; TN: True Negatives; G6PD: Glucose-6-Phosphate Dehydrogenase; DTA: Diagnostic Test Accuracy; U.S.: United States of America; U.K.: United Kingdom; FCDO: Foreign, Commonwealth & Development Office; fdn.: foundation; DFAT Department of Foreign Affairs and Trade, DFID: Department for International Development; MORU: Mahidol Oxford Tropical Medicine Research Unit

Table 2. Pooled DTA values for each threshold defined by StandardTM G6PD (SD Biosensor) test.

	G6PD activity threshold	Sensitivity (95%CI) & CoE	Specificity (95%CI) & CoE	+LR (95%CI)	-LR (95%CI)	
	30%	99.1% (96.9%-99.7%) (4 studies, 3122 participants)	97.4% (95.2-98.4%) (4 studies, 3122 participants)	35.3	0.009 (0.003-0.031)	
		High ⊕⊕⊕⊕	High ⊕⊕⊕⊕	(20.7-60.5)		
	70%	95.7% (92.9-97.4%) 92.8% (85.8-96.5%) (4 studies, 2371 participants) (4 studies, 2371 participants)		13.2	0.046	
	1070	High ⊕⊕⊕⊕	High ⊕⊕⊕⊕	(6.8-26.5)	(0.030-0.073)	
medRxiv preprint do (which was not	: https://doi.org/10.1101 certified by peer revie	/2024.02.10.24302326; this version posted Febru w) is the author/funder, who has granted medRxiv made available under a CO 2014.04 Memational	ary 11, 2024. The copyright holder for this prepring a license to display the preprint in perpetuity license:	8.2	0.106	
	5570	Low ⊕⊕○○	Moderate ⊕⊕⊕⊖	(4.1-16.0)	(0.049-0.227)	

Abbreviations: CI: confidence interval, LR: likelihood ratio, +: positive, -: negative, CoE: Certainty of the Evidence